Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:11:51.905Z.
Calculation as of: 2026-10-06T15:11:51.905Z.
Quote observation: 2026-10-06T15:10:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4f3bc52aaee10dc4864d073eee8720ed85d0d11e7a3d16422bde167dd05b99a5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$93.51M
EBITDA Yield
N/A
TTM Avg
2.46%
3Y Avg
2.46%
5Y Avg
2.46%
Market Cap
$94.35M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| electroCore, Inc. (ECOR) | $92.64M | N/A | N/A | N/A | N/A |
| Biomea Fusion, Inc. (BMEA)vs › | $91.82M | N/A | N/A | N/A | N/A |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $93.51M | N/A | 2.46% | 2.46% | 2.46% |
| Equillium, Inc. (EQ)vs › | $90.41M | N/A | N/A | N/A | N/A |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $94.35M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $89.91M | N/A | N/A | N/A | N/A |
| ImmuCell Corporation (ICCC)vs › | $89.11M | 6.74% | 6.57% | 5.72% | 4.64% |
| Korro Bio, Inc. (KRRO)vs › | $96.75M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.90M | 21.57% | 23.06% | 41.09% | 38.38% |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $97.54M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute